Delivery Order SPE2DB22D2206-SPE2DB26FDV95
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,109.65 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. Awarded on August 11, 2025, with completion expected by August 12, 2025, this firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,257.06 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a pharmaceutical product used primarily for treating overactive bladder. The contract was competitively awarded without a set-aside designation under a firm fixed-price arrangement, with the ultimate completion date set for June 18, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania served as the place of performance. This...
- The Defense Logistics Agency awarded a $14,781.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a prescription medication used to treat overactive bladder. The contract is a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and was awarded on a non-competitive basis with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $5,313.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a medication used to treat overactive bladder. The contract, awarded on October 30, 2025, with an ultimate completion date of October 31, 2025, was competitively awarded with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,996.61 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used to treat overactive bladder. The award was competitively procured with no set-aside designation and carries a firm fixed price structure. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. The contract is scheduled for ultimate completion by July 15,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,190.97 to supply 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. This competitively awarded, non-set-aside delivery order is classified as firm fixed price and carries an ultimate completion date of September 29, 2025. The award was issued on September 26, 2025, with performance to occur at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $38,869.51 delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This firm fixed-price, competitively awarded delivery order is scheduled for completion by July 28, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award carries no set-aside designation and represents a routine pharmaceutical procurement through the federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $6.5K to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. The award was made on September 16, 2025, under a firm fixed price contract type with an ultimate completion date of September 17, 2025. This non-set-aside delivery order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at approximately $53K, for 90-count tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This competitive, non-set-aside award was issued on September 24, 2025, with an ultimate completion date of September 25, 2025. The contract utilizes firm fixed pricing and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at approximately $45K for 90-count tablets of Myrbetriq ER 25 mg, a medication used to treat overactive bladder. Issued on October 17, 2025, with completion targeted for October 20, 2025, this firm fixed-price delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. The award carried no set-aside designation, indicating it was competitively awarded among...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDV95Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,974.63 for 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. The award, issued on October 31, 2025, is a firm fixed-price contract with an ultimate completion date of November 3, 2025. This is a competitive, non-set-aside award issued to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, and represents performance delivery at the same location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's substantial federal pharmaceutical procurement portfolio demonstrates its established capability as a critical vendor for federal medical supply chain operations across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 10/31/25 |